Frequently Asked Questions about Rapport Therapeutics, Inc. Common Stock (RAPP)

Name: Rapport Therapeutics, Inc. Common Stock (RAPP) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Rapport Therapeutics, Inc. Common Stock (RAPP) do?

Accepted Answer

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein ...

Question 2

Is Rapport Therapeutics, Inc. Common Stock (RAPP) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of RAPP reveals an Altman Z-Score of 26.38 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if RAPP fits their risk profile.

Question 3

What is the current P/E ratio for RAPP?

Accepted Answer

As of the latest trading session, Rapport Therapeutics, Inc. Common Stock (RAPP) has a trailing P/E ratio of -13.32.

Question 4

Who is the CEO of Rapport Therapeutics, Inc. Common Stock?

Accepted Answer

The current Chief Executive Officer of Rapport Therapeutics, Inc. Common Stock is Abraham N. Ceesay.

Question 5

What was RAPP's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Rapport Therapeutics, Inc. Common Stock reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022) respectively.

Question 6

Does RAPP pay a dividend?

Accepted Answer

Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does RAPP have?

Accepted Answer

In its latest reporting period, Rapport Therapeutics, Inc. Common Stock generated $-0.09B in Free Cash Flow against a total debt load of $0.01B.

Question 8

What is the Price-to-Book (P/B) ratio of Rapport Therapeutics, Inc. Common Stock?

Accepted Answer

The Price-to-Book (P/B) ratio for Rapport Therapeutics, Inc. Common Stock (RAPP) is currently 3.06.

Question 9

What is the Price-to-Sales (P/S) ratio of RAPP?

Accepted Answer

Based on trailing twelve-month data, Rapport Therapeutics, Inc. Common Stock (RAPP) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Rapport Therapeutics, Inc. Common Stock's Return on Equity (ROE)?

Accepted Answer

Rapport Therapeutics, Inc. Common Stock (RAPP) has a Return on Equity (ROE) of -28.85%, representing its profitability relative to shareholder equity.